CLINICAL_TRIALS ClinicalTrials.gov record update

An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of 3 New Formulations of Premarin® /MPA 0.625 mg/2.5 mg Compared With Reference Formulation of Premarin®/MPA in Healthy Postmenopausal Women

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00630435
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:34:56.866339+00:00
Published At: 2009-02-04T00:00:00+00:00
Record Updated At: 2009-02-04
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Menopause"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2009-02-04"
protocolSection.identificationModule.nctId: "NCT00630435"
protocolSection.identificationModule.officialTitle: "An Open-Label, Single-Dose, Randomized, 4-Period, Crossover, Bioequivalence Study of 3 New Formulations of Premarin\u00ae /MPA 0.625 mg/2.5 mg Compared With Reference Formulation of Premarin\u00ae/MPA in Healthy Postmenopausal Women"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.